Azitra Inc Stock Price, News & Analysis

Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in The Microcap Conference 2025. The presentation is scheduled for January 29, 2025, at 11:00 a.m. ET at the Borgata Hotel Casino & Spa in Atlantic City, NJ.

Chief Executive Officer Francisco Salva will lead the presentation in Studio C. During the conference, which runs from January 28-30, 2025, the company's management team will engage in one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing Azitra's business and clinical development strategy, recent corporate achievements, and upcoming milestones.

Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the pricing of its public offering of 4,857,780 shares of common stock at $0.30 per share. The offering is expected to generate gross proceeds of approximately $1.5 million before deducting placement agent fees and other expenses.

The offering is scheduled to close on January 16, 2025, subject to customary conditions. The company plans to use the net proceeds for working capital and general corporate purposes. Maxim Group is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.

Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the commencement of a public offering of common stock and pre-funded warrants. Maxim Group will serve as the sole placement agent for the offering.

The company plans to utilize the net proceeds for working capital and general corporate purposes. The offering is being conducted through an effective shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and declared effective on July 8, 2024. The completion, size, and terms of the offering are subject to market conditions and cannot be guaranteed.

Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in Biotech Showcase 2025. The event will take place from January 13-15, 2025 in San Francisco, with Azitra's presentation scheduled for January 13 at 3:00 p.m. PT at the Hilton San Francisco Union Square.

Chief Operating Officer Travis Whitfill will lead the presentation, and the company's management team will conduct one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing Azitra's business strategy, clinical development plans, recent achievements, and future milestones.

The Biotech Showcase, organized by Demy-Colton and EBD Group, serves as a leading investor conference for private and micro-mid-cap biotechnology companies to present their innovations and connect with investors.

Azitra (AZTR) reported Q3 2024 financial results and business updates. Key highlights include completing a $10 million follow-on offering, dosing the first Netherton syndrome patient with ATR-12, and receiving FDA Fast Track designation for ATR-04. Financial results show zero service revenue compared to $310,700 in Q3 2023, R&D expenses of $1.0 million (up from $0.5 million), and G&A expenses of $1.9 million. The company reported a net loss of $1.0 million and held cash and equivalents of $7.3 million as of September 30, 2024. Upcoming milestones include initial safety data and first patient dosing for key trials in Q1 2025.

Azitra (NYSE American: AZTR) announces its participation at BIO-Europe 2024 in Stockholm, Sweden, scheduled for Monday, November 4, 2024, at 2:30pm CET. Travis Whitfill, Chief Operating Officer, will deliver a corporate presentation highlighting the company's pipeline progress, particularly focusing on two key developments: ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-induced dermal toxicity.

The company reports significant achievements in 2024, including the first patient dosing with ATR-12 and receiving FDA Fast Track designation for ATR-04. The presentation will take place at Stockholmsmässan, with opportunities for one-on-one meetings through the BIO One-on-One Partnering system.

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has been invited to present at the 2024 Maxim Healthcare Virtual Summit. The event, hosted by Maxim Group , will take place from October 15-17, 2024.

Azitra's Chief Operating Officer, Travis Whitfill, will participate in a panel presentation on Thursday, October 17, 2024, at 2:00 p.m. ET. The presentation will be part of the rare disease panel, featuring Azitra alongside other companies such as Quoin Pharmaceuticals, Rezolute, and Zevra Therapeutics.

The summit will showcase a range of biotechnology, diagnostic, medical device, and healthcare information technology companies. Maxim Senior Analysts will host interactive discussions with CEOs and key management, providing insights into various healthcare sectors.

Azitra, Inc. (NYSE American: AZTR) announced a late-breaking presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam. Dr. Mary Spellman will present on September 26, 2024, discussing the development of ATR-04, a live biotherapeutic product for treating epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity.

ATR-04 is an engineered Staphylococcus epidermidis strain designed to be safer by deleting an antibiotic resistance gene and controlling growth through auxotrophy. It targets EGFRi-associated skin toxicity, which affects approximately 150,000 patients in the United States. Azitra has an active IND for a Phase 1/2 clinical trial of ATR-04, which has received Fast Track designation from the FDA.

The presentation will cover ATR-04's preclinical development and details of the planned clinical trial. It will be available on Azitra's website after the event.

Azitra (NYSE American: AZTR) has received Fast Track Designation from the FDA for ATR-04, a topical treatment for moderate to severe skin rash caused by Epidermal Growth Factor Receptor inhibitors (EGFRi). This designation recognizes the unmet medical need for treating EGFRi-associated dermal toxicity, which affects approximately 150,000 patients in the US, representing a $1 billion market opportunity.

ATR-04 is a live biotherapeutic product containing an engineered Staphylococcus epidermidis strain. Azitra plans to initiate a Phase 1/2 clinical trial by the end of 2024. The Fast Track status may accelerate ATR-04's development and review process, potentially offering cancer patients a much-needed alternative to current off-label treatments or therapy discontinuation.